Pashtun Shahim, MD; Yelverton Tegner, MD, PhD; David H. Wilson, PhD; et al.
free access
JAMA Neurol. 2014;71(6):684-692. doi:10.1001/jamaneurol.2014.367
Shahim et al determine whether sports-related concussion is associated with elevated levels of blood biochemical markers of injury to the central nervous system and assess whether plasma levels of these biomarkers predict return to play in professional ice hockey players with sports-related concussion. Gatson and Diaz-Arrastia provide commentary in a related editorial.
-
Editorial
Tau as a Biomarker of Concussion
Joshua Gatson, PhD; Ramon Diaz-Arrastia, MD, PhD
JAMA Neurol
Michael Wall, MD; Mark J. Kupersmith, MD; Karl D. Kieburtz, MD, MPH; et al.
free access
JAMA Neurol. 2014;71(6):693-701. doi:10.1001/jamaneurol.2014.133
Wall and colleagues reported the baseline clinical and laboratory features of patients enrolled in the Idiopathic Intracranial Hypertension Treatment Trial. Volpe provided a related .
David B. Burkholder, MD; Vlastimil Sulc, MD; E. Matthew Hoffman, DO, PhD; et al.
free access
JAMA Neurol. 2014;71(6):702-709. doi:10.1001/jamaneurol.2014.585
Burkholder and colleagues determine whether the following are associated with surgical outcomes in patients with magnetic resonance imaging-negative temporal lobe epilepsy who underwent standard anterior temporal lobectomy: (1) unilateral-only interictal epileptiform discharges on preoperative scalp electroencephalogram; (2) complete resection of tissue generating interictal epileptiform discharges on electrocorticography; (3) complete resection of opioid-induced interictal epileptiform discharges recorded on electrocorticography; and (4) location of interictal epileptiform discharges recorded on electrocorticography.
Sotirios A. Parashos, MD, PhD; Sheng Luo, MS; Kevin M. Biglan, MD, MPH; et al.
free access
JAMA Neurol. 2014;71(6):710-716. doi:10.1001/jamaneurol.2014.391
In an inception cohort analysis of data from 413 patients with early, untreated Parkinson disease who were enrolled in 2 multicenter, randomized, double-blind clinical trials, Parashos and coauthors examine the value of measures of impairment, disability, and quality of life in assessing progression in early Parkinson disease.
Gregory S. Day, MD, MSc, BScH; Simin Laiq, MD; David F. Tang-Wai, MD, FRCPC; et al.
free access
JAMA Neurol. 2014;71(6):717-724. doi:10.1001/jamaneurol.2014.488
To characterize the organization of neuroglial elements within ovarian teratomas resected from patients with NMDAR encephalitis, Day et al performed a case-control study. Outcome measures were atypical CNS neuronal elements in ovarian teratomas resected from cases vs controls and the relationship between atypical neurons and immune infiltrates.
Niklas Mattsson, MD, PhD; Philip S. Insel, MS; Rachel Nosheny, PhD; et al.
free access
JAMA Neurol. 2014;71(6):725-734. doi:10.1001/jamaneurol.2014.446
Mattsson et al test the hypothesis that the development of Aβ pathology is related to increased regional atrophy in the brains of cognitively normal (CN) persons. They studied 47 CN control subjects and 15 patients with AD dementia. The main outcome measures were group effects on regional gray matter volumes at baseline and over time.
Melinda S. Burnett, MD; Robert J. Witte, MD; J. Eric Ahlskog, PhD, MD
free access
JAMA Neurol. 2014;71(6):735-741. doi:10.1001/jamaneurol.2014.286
In a blinded, retrospective case-control study using medical records from 2000 to 2007 obtained from an magnetic resonance imaging (MRI) database at the Mayo Clinic in Rochester, Minnesota, Burnett and coauthors determine the clinical features associated with Swiss cheese striatum detected on MRI scans.
Ge Li, MD, PhD; Steven P. Millard, PhD; Elaine R. Peskind, MD; et al.
free access
JAMA Neurol. 2014;71(6):742-751. doi:10.1001/jamaneurol.2014.445
Li et al examine biomarkers indicative of age-related cognitive decline among older individuals with normal cognition in a cross-sectional and longitudinal study.
Roy N. Alcalay, MD, MS; Tama Dinur, PhD; Timothy Quinn, BS; et al.
free access
JAMA Neurol. 2014;71(6):752-757. doi:10.1001/jamaneurol.2014.313
Alcalay and colleagues estimate the age-specific risk of PD in Ashkenazi Jewish patients with type 1 GD and in GBA heterozygotes.
Ing-Tsung Hsiao, PhD; Yi-Hsin Weng, MD; Chia-Ju Hsieh, MSc; et al.
free access
has multimedia
JAMA Neurol. 2014;71(6):758-766. doi:10.1001/jamaneurol.2014.290
Hsiao and colleagues used [18F]9-fluoropropyl-(+)-dihydrotetrabenazine (18F-DTBZ) positron emission tomography to explore the characteristics of vesicular monoamine transporter type 2 imaging in patients with Parkinson disease (PD) with different severity levels as well as to investigate its capability in monitoring clinical severity.
-
Video:
[
18F]9-fluoropropyl-(+)-dihydrotetrabenazine From Normal to Advanced Parkinson Disease